Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30
Renalytix plc (NASDAQ: RNLX) will report its first quarter fiscal year 2023 financial results on November 30, 2022, before market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) will report its first quarter fiscal year 2023 financial results on November 30, 2022, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the results, business strategy, regulatory processes, and partnerships. Renalytix is a leader in bioprognosis for kidney health, with its flagship product, KidneyIntelX™, receiving Breakthrough Designation from the FDA to improve kidney disease prognosis and management.
Positive
- KidneyIntelX™ received Breakthrough Designation from the FDA.
Negative
- None.
Details
News Market Reaction – RNLX
The recorded move for RNLX in the trading session of this news was -2.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and SALT LAKE CITY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2023 financial results on Wednesday, November 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.
Webcast Registration link: https://edge.media-server.com/mmc/p/88vepbze
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
For further information, please contact:
| Renalytix plc | www.renalytix.com | ||
| James McCullough, CEO | Via Walbrook PR | ||
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | ||
| Alex Price / Nicholas Moore | |||
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | ||
| Gary Clarence / Daniel Adams | |||
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | ||
| Paul McManus / Lianne Applegarth / Alice Woodings | Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 | ||
| CapComm Partners | |||
| Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com | ||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.